The product candidate is designed to treat mild to moderate dementia of the Alzheimer’s type.
ALZN002 is a proprietary “active” immunotherapy product, which means each patient’s immune system produces it.
It consists of autologous dendritic cells (DCs) that are activated white blood cells taken from each patient so that they can be engineered outside of the body to attack Alzheimer’s-related amyloid-beta proteins.
These DCs are pulsed with a novel amyloid-beta peptide designed to bolster the ability of the patient’s immune system to combat Alzheimer’s.
The ALZN002-01 Phase 1/2A trial will assess the safety, tolerability, and efficacy of multiple ascending doses of ALZN002 compared to placebo in 20‑30 subjects with mild to moderate dementia of the Alzheimer’s type.
Price Action: ALZN shares are down 6.78% at $1.10 on the last check Thursday.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok
